Equities

ATAI Life Sciences NV

ATAI Life Sciences NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.26
  • Today's Change0.02 / 1.61%
  • Shares traded485.60k
  • 1 Year change-10.64%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

  • Revenue in USD (TTM)378.00k
  • Net income in USD-58.07m
  • Incorporated2020
  • Employees83.00
  • Location
    ATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
  • Phone+49 8 921539035
  • Fax+49 89 215390351
  • Websitehttps://atai.life/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Caribou Biosciences Inc33.11m-123.44m187.95m158.00--0.6054--5.68-1.39-1.390.37633.440.0917--15.61209,576.00-34.17---37.56-------372.78-----1,231.110.00--148.91---2.66------
CytoDyn Inc0.00-51.32m197.79m9.00---------0.0527-0.05270.00-0.11030.00----0.00-444.45-259.15-----------232,918.20---2.76--------35.70------
Vaxart Inc13.93m-75.66m204.72m109.00--2.56--14.70-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
Gossamer Bio Inc95.84m-80.85m206.12m135.00--2.53--2.15-0.3996-0.39960.4340.36040.3453----709,940.80-29.13-57.43-34.41-64.38-----84.36-----7.070.7073------21.61------
MacroGenics Inc41.02m-136.37m206.98m339.00--3.58--5.05-2.19-2.190.65830.92180.16196.626.51120,997.00-53.82-37.76-67.56-45.5379.37---332.47-133.962.69-172.620.00---61.33-0.460692.44---41.13--
ATAI Life Sciences NV378.00k-58.07m208.07m83.00--1.24--550.45-0.3852-0.38520.00231.000.0016--0.03314,554.22-24.68---26.93-------15,320.63-----90.710.0992--34.76--73.60------
Fulcrum Therapeutics Inc81.63m-20.23m214.66m76.00--0.7821--2.63-0.3507-0.35071.314.400.2746--29.131,074,079.00-6.81-50.55-7.14-55.91-----24.79-1,189.10----0.00---55.77--11.41---43.70--
Pyxis Oncology Inc16.15m-59.20m215.73m51.00--1.27--13.36-1.26-1.260.32692.880.0842----322,920.00-30.87---33.12--97.06---366.67------0.0008------38.87------
Cabaletta Bio Inc0.00-89.98m218.84m136.00--1.08-----1.92-1.920.004.130.00----0.00-44.76-33.76-47.90-35.68------------0.00-------27.75------
Codexis Inc60.89m-76.36m220.58m174.00--3.59--3.62-1.09-1.090.87230.86650.35956.273.58349,942.50-45.08-17.13-56.05-20.2377.9577.29-125.41-37.042.92--0.3158---49.392.97-126.96--9.80--
Compass Therapeutics Inc.850.00k-47.24m224.27m32.00--1.54--263.85-0.3573-0.35730.00641.060.0051----26,562.50-28.22-41.75-29.94-46.41-----5,557.88------0.00-------8.33---56.91--
Omeros Corp0.00-199.92m227.73m198.00---------3.32-2.350.00-2.150.00----0.00-45.24-55.51-58.74-70.10-----------5.741.42------3.91---5.56--
XBiotech Inc0.00-35.01m228.47m94.00--1.16-----1.15-1.150.006.460.00----0.00-15.5331.88-16.3233.27------877.30----0.04840.00-100.00--25.36--24.30--
Nektar Therapeutics93.16m-177.08m231.94m137.00--2.91--2.49-0.9007-0.90070.47470.43290.22242.1673.61679,978.10-42.28-31.02-48.54-34.6359.2278.04-190.09-372.214.90-18.760.00---2.10-40.3525.03---42.89--
Data as of Sep 19 2024. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD

Institutional shareholders

5.69%Per cent of shares held by top holders
HolderShares% Held
Walleye Capital LLCas of 30 Jun 20242.76m1.65%
Morgan Stanley Investment Management, Inc.as of 30 Jun 20241.78m1.06%
BlackRock Fund Advisorsas of 30 Jun 2024850.20k0.51%
Morgan Stanley & Co. LLCas of 30 Jun 2024848.22k0.51%
Brown University Investment Officeas of 30 Jun 2024718.50k0.43%
Two Sigma Investments LPas of 30 Jun 2024717.13k0.43%
Millennium Management LLCas of 30 Jun 2024648.19k0.39%
BlackRock Advisors (UK) Ltd.as of 30 Jun 2024454.30k0.27%
The Vanguard Group, Inc.as of 30 Jun 2024411.48k0.25%
Fiduciary Trust International LLCas of 30 Jun 2024356.36k0.21%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.